Graney & King’s Anavex Life Sciences AVXL Stock Holding History

Graney & King’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,000	Closed	-$8.9K	–	358
2025 Q3	$8.9K	Hold	1,000	–	–	0.01%	241
2025 Q2	$9.22K	Buy	+1,000	New	+$8.54K	0.01%	225

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Graney & King's AVXL Position: Q4 2025 in Review

Graney & King sold out of Anavex Life Sciences (AVXL) in Q4 2025, closing a stake of 1,000 shares — an estimated $8.9K sold.

Graney & King first reported a position in AVXL in Q2 2025 and held it in 2 quarters. The position peaked at $9.22K in Q2 2025. 184 funds tracked by Wall St. Rank hold AVXL as of Q4 2025.

Graney & King reported no remaining Anavex Life Sciences position as of Q4 2025 after selling out during the quarter.
Graney & King sold 1,000 Anavex Life Sciences shares in Q4 2025, an estimated $8.9K.
Graney & King first reported a position in Anavex Life Sciences in Q2 2025 and held it in 2 quarters.
Graney & King's Anavex Life Sciences position peaked at $9.22K in Q2 2025.
184 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2025.

Based on Graney & King's 13F filing for Q4 2025, filed 13 Feb 2026.